Aaron Prendergast
About
Aaron Prendergast is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Aaron Prendergast has authored 21 papers receiving a total of 362 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 8 papers in Surgery. Recurrent topics in Aaron Prendergast's work include Renal cell carcinoma treatment (6 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Aaron Prendergast is often cited by papers focused on Renal cell carcinoma treatment (6 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Aaron Prendergast collaborates with scholars based in United Kingdom, Spain and France. Aaron Prendergast's co-authors include Kelly Mousa, Alejo Rodríguez‐Vida, Cristina Suárez, Thomas Powles, María José Méndez-Vidal, Christy Ralph, Hilary Glen, Fiona Thistlethwaite, Gopalakrishnan Srinivasan and James Larkin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Gut.
In The Last Decade
Aaron Prendergast
20 papers receiving 361 citations
Peers
Aaron Prendergast
L. Sengeløv Denmark
Theodore Stewart Gourdin United States
Mariel Elena Boyd United States
Shengliang Shi China
Benjamin Miron United States
Carmen Mir Spain
Viktoria Stühler Germany
Nieves Martínez Chanzá Belgium
Victoria Hinder New Zealand
Oleg Karyakin Sweden
Citations per year, relative to Aaron Prendergast Aaron Prendergast (= 1×)
peers
L. Sengeløv
Countries citing papers authored by Aaron Prendergast
Since
Specialization
Citations
This map shows the geographic impact of Aaron Prendergast's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Prendergast with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Prendergast more than expected).
Fields of papers citing papers by Aaron Prendergast
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Aaron Prendergast. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Prendergast. The network helps show where Aaron Prendergast may publish in the future.
Co-authorship network of co-authors of Aaron Prendergast
This figure shows the co-authorship network connecting the top 25 collaborators of Aaron Prendergast. A scholar is included among the top collaborators of Aaron Prendergast based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron Prendergast. Aaron Prendergast is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Suárez, Cristina, James Larkin, Begoña P. Valderrama, et al.. (2023). Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). Journal of Clinical Oncology. 41(14). 2493–2502.
2.
Yang, Yao‐Hsu, Cankut Çubuk, Romain Banchereau, et al.. (2023). 2393P Ephrin signalling mediates resistance to programmed death ligand 1 (PD-L1) inhibition in urothelial carcinoma (UC). Annals of Oncology. 34. S1218–S1218.
3.
Nathan, Paul, Jennifer Allison, Natalie Charnley, et al.. (2023). Real-world outcomes of cabozantinib treatment after first-line checkpoint inhibitor-based combination therapy for patients with advanced renal cell carcinoma: CARINA study results. European Urology Open Science. 57. S238–S239.
4.
Tan, Wei Shen, Aaron Prendergast, Charlotte Ackerman, et al.. (2022). Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. European Urology. 83(6). 497–504.
5.
Powles, Thomas, María José Méndez-Vidal, Alejo Rodríguez‐Vida, et al.. (2022). CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer.. Journal of Clinical Oncology. 40(17_suppl). LBA4503–LBA4503.
6.
Schmid, Peter, Duncan Wheatley, Pankaj G. Roy, et al.. (2021). 208P ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC. Annals of Oncology. 32. S449–S450.
7.
Szabados, Bernadett, Alejo Rodríguez‐Vida, Ignacio Durán, et al.. (2021). Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. European Urology Oncology. 4(3). 456–463.
8.
Cathcart, Paul, Caroline M. Moore, Hashim U. Ahmed, et al.. (2021). Outcomes of the RAFT trial: robotic surgery after focal therapy. British Journal of Urology. 128(4). 504–510.
9.
Szabados, Bernadett, et al.. (2021). Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer. European Urology Oncology. 4(6). 943–947.
10.
Schmid, Peter, Mark Kockx, Sung‐Bae Kim, et al.. (2021). Abstract PD14-06: Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER+ primary breast cancer. Cancer Research. 81(4_Supplement). PD14–6.
11.
Rodríguez, C. Suárez, James Larkin, Poulam M. Patel, et al.. (2021). Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.. Journal of Clinical Oncology. 39(15_suppl). 4511–4511.
12.
Schmid, Peter, Begoña Bermejo, Melissa Phillips, et al.. (2021). 123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer. Annals of Oncology. 32. S411–S412.
13.
Szabados, Bernadett, Alejo Rodríguez‐Vida, Ignacio Durán, et al.. (2020). 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis. Annals of Oncology. 31. S1319–S1319.
14.
Rodríguez, C. Suárez, James Larkin, Poulam M. Patel, et al.. (2020). Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.. Journal of Clinical Oncology. 38(6_suppl). 619–619.
15.
Kocher, Hemant M., Bristi Basu, Fieke E. M. Froeling, et al.. (2019). STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer. Annals of Oncology. 30. v267–v267.
16.
Powles, Thomas, James Larkin, Poulam M. Patel, et al.. (2019). A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).. Journal of Clinical Oncology. 37(7_suppl). 545–545.
17.
Cross, Amanda J., Kate Wooldrage, Ines Kralj‐Hans, et al.. (2018). Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study. Gut. 68(9). 1642–1652.
18.
Schmid, Peter, Jacinta Abraham, Stephen Chan, et al.. (2018). AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.. Journal of Clinical Oncology. 36(15_suppl). 1007–1007.
19.
Schmid, Peter, Fiona Blackhall, D. Muthukumar, et al.. (2017). A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers. Annals of Oncology. 28. v638–v638.
20.
Prendergast, Aaron, Kara Martin, Padraig Doolan, et al.. (2011). P5-13-12: Can the Ki67 Proliferation Index Predict the Oncotype DX Recurrence Score in Lymph Node Negative, ER Positive Breast Cancer?. Cancer Research. 71(24_Supplement). P5–13.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by L. Sengeløv Breakdown of academic impact, for papers by Theodore Stewart Gourdin Breakdown of academic impact, for papers by Mariel Elena Boyd Breakdown of academic impact, for papers by Shengliang Shi Breakdown of academic impact, for papers by Benjamin Miron Breakdown of academic impact, for papers by Carmen Mir Breakdown of academic impact, for papers by Viktoria Stühler Breakdown of academic impact, for papers by Nieves Martínez Chanzá Breakdown of academic impact, for papers by Victoria Hinder Breakdown of academic impact, for papers by Oleg Karyakin